Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: A phase I study

Lung Cancer

Volumn 38, Issue 1, 2002, Pages 65-71

  Huffman, Philip C ^a   Cohen, Ezra E W ^a   Masters, Gregory A ^a   Haraf, Daniel J ^a   Mauer, Ann M ^a   Rudin, Charles M ^a   Krauss, Stuart A ^a   Huo, Dezheng ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Carboplatin; Concomitant chemoradiotherapy; Non small cell lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; ESOPHAGITIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MORTALITY; NEUTROPENIA; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; RADIATION PNEUMONIA; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036805929     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00144-7     Document Type: Article

References (21)

1. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88:1996;1210-1215.
2. Sause W., Kolesar P., Taylor S.I., et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest. 117:2000;358-364. (Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group).
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials, BMJ 1995;311:899-909.
4. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 17:1999;2692-2699.
5. Curran W., Scott C., Langer C. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer. Lung Cancer. 29:2000;93. (report of Radiation Therapy Oncology Group 9410, 9th World Conference on Lung Cancer).
6. Mauer A.M., Masters G.A., Haraf D.J., et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J. Clin. Oncol. 16:1998;159-164.
7. Masters G.A., Haraf D.J., Hoffman P.C., et al. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies. J. Clin. Oncol. 16:1998;2157-2163.
8. Vokes E., Leopold K.A., Herndon J.E. II, et al. A randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer (CALGB study 9431). Proc. Am. Soc. Clin. Oncol. 18:1999;459a.
9. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756.
10. Choy H., Akerley W., Safran H., et al. Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J. Clin. Oncol. 16:1998;3316-3322.
11. Gandara D., Lovato L.C., Albain K.S., et al. Prolonged survival in pathologic stage IIIB non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy followed by consolidation docetaxel. Proc. Am. Soc. Clin. Oncol. 19:2000;490a. (a phase II study (S9504) of the Southwest Oncology Group (SWOG)).
12. Lyss A.P., Perry M.C., Goutsou M., et al. Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. Am. J. Clin. Oncol. 15:1992;399-404. (a phase II trial of the Cancer and Leukemia Group B).
13. Gandara D.R., Crowley J., Livingston R.B., et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer. J. Clin. Oncol. 11:1993;873-878. (a phase III study of the Southwest Oncology Group).
14. Jacoulet P., Breton J.L., Westeel V., et al. Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer. 12:1995;247-257.
15. Colleoni M., Boni L., Vicario G., et al. A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer. Oncology. 53:1996;364-368.
16. Pronzato P., Ghio E., Losardo P.L., et al. Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 37:1996;610-612.
17. Garst J., Crawford J., O'Rourke O., Herndon J. Vinorelbine and carboplatin for the treatment of patients with advanced non-small cell lung cancer. A phase II response, toxicity and survival study. Proc. Am. Soc. Clin. Oncol. 15:1996;404.
18. Horvath L., Boyer M., Clarke S., et al. Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer. Lung Cancer. 32:2001;173-178.
19. Agelaki S., Bania H., Kouroussis C., et al. Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. Lung Cancer. 34:(4):2001;S77-S80.
20. Santomaggio C., Tucci E., Rinaldini M., et al. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am. J. Clin. Oncol. 21:1998;67-71.
21. Vincent M., Rorke S., Tomiak A., et al. 'Carnavel' a retrospective experience with combination vinorelbine (VLB) and carboplatinum (Carbo) in 35 patients with stage III/IV non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;536a.